Stereotactic Radiotherapy for Oligo-Progressive Metastatic Cancer (The STOP Trial)

NAActive, not recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

July 31, 2022

Study Completion Date

June 30, 2026

Conditions
Metastatic Cancer
Interventions
RADIATION

Stereotactic Ablative Radiotherapy (SABR)

Patients will receive stereotactic ablative radiotherapy to all sites of progressive disease, with continuation of current systemic agents.

OTHER

Standard of Care Treatment

"May include:~* Continue with current systemic agent(s)~* Observation~* Switch to next-line treatment~Palliative radiotherapy is allowed in this arm."

Trial Locations (7)

T6G 1Z2

Alberta Health Services-Cross Cancer Institute, Edmonton

V2M 7E9

BC Cancer - Prince George, Prince George

V3V 1Z2

BC Cancer Fraser Valley Centre, Surrey

V5Z 4E6

BC Cancer Agency Branch, Vancouver

V8R 4X1

BC Cancer - Victoria Centre, Victoria

N6A 4L6

London Regional Cancer Program, London

M5G1X6

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

NCT02756793 - Stereotactic Radiotherapy for Oligo-Progressive Metastatic Cancer (The STOP Trial) | Biotech Hunter | Biotech Hunter